Its an unusual situation if a buyout were to occur (and I am not suggesting anything either :-)) with the (presumably) growth portion of AUXL being Xiaflex that brings Biospecifics and their 10-11% in the mix with any buyout. I could see Pfizer going either way being disinterested and returning the product or wanting to get US rights. Unfortunately right now I would lean towards the former which could create lots of other buyout opportunities but not after a big hit to the stocks.
News 
Market Data 
Discover 
